CHINA – Lynk Pharmaceuticals, a Hangzhou, China-based clinical stage company, raised 200M RMB in Series C1 funding.
The round saw participation from China Grand Prosperity Investment, Tailong Capital and Liando Investment. The company intends to use the funds to accelerate the clinical development of its core products.Led by Dr. Zhao-Kui (ZK) Wan, Chairman and CEO, Lynk Pharmaceuticals specializes in the development of small molecule FIC and BIC drugs for oncology and autoimmune diseases. Its core team has deep knowledge in medicinal chemistry, biology, clinical and commercial development, with an average of more than 20 years of experience in new drug research and development or related disciplines in the pharmaceutical industry. The company emphasizes innovation and differentiation in its pipeline, with a focus on the development of highly selective second-generation and tissue-restricted third-generation JAK inhibitors while exploring drug development with novel targets. Currently, Lynk has 4 Phase II clinical trials for four indications with promising clinical data. Among these, a few programs are expected to enter Phase III clinical trials in the near future. Additional pipeline candidates have shown promising clinical and preclinical data and have the potentials to become BIC/FIC drugs for several indications. 01/06/2023
